557 related articles for article (PubMed ID: 22506086)
1. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
4. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis.
Santa-Rita RM; Henriques-Pons A; Barbosa HS; de Castro SL
J Antimicrob Chemother; 2004 Oct; 54(4):704-10. PubMed ID: 15329361
[TBL] [Abstract][Full Text] [Related]
5. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
6. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
Escobar P; Matu S; Marques C; Croft SL
Acta Trop; 2002 Feb; 81(2):151-7. PubMed ID: 11801222
[TBL] [Abstract][Full Text] [Related]
7. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani.
Azzouz S; Maache M; Dos Santos MF; Sarciron ME; Petavy AF; Osuna A
J Parasitol; 2006 Oct; 92(5):877-83. PubMed ID: 17152926
[TBL] [Abstract][Full Text] [Related]
8. Pterocarpanquinone LQB-118 induces apoptosis in Leishmania (Viannia) braziliensis and controls lesions in infected hamsters.
Costa L; Pinheiro RO; Dutra PM; Santos RF; Cunha-Júnior EF; Torres-Santos EC; da Silva AJ; Costa PR; Da-Silva SA
PLoS One; 2014; 9(10):e109672. PubMed ID: 25340550
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol analogues present effective antileishmanial activity against promastigotes and amastigotes from distinct Leishmania species by multitarget action in the parasites.
Antinarelli LMR; Meinel RS; Coelho EAF; da Silva AD; Coimbra ES
J Pharm Pharmacol; 2019 Dec; 71(12):1854-1863. PubMed ID: 31595530
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine.
Varela-M RE; Mollinedo-Gajate C; Muro A; Mollinedo F
Acta Trop; 2014 Mar; 131():32-6. PubMed ID: 24299925
[TBL] [Abstract][Full Text] [Related]
12. Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp.
Calixto SL; Glanzmann N; Xavier Silveira MM; da Trindade Granato J; Gorza Scopel KK; Torres de Aguiar T; DaMatta RA; Macedo GC; da Silva AD; Coimbra ES
Chem Biol Interact; 2018 Sep; 293():141-151. PubMed ID: 30098941
[TBL] [Abstract][Full Text] [Related]
13. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis.
Terreros MJS; de Luna LAV; Giorgio S
Parasitol Int; 2019 Aug; 71():163-166. PubMed ID: 30991111
[TBL] [Abstract][Full Text] [Related]
15. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
16. Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.
Lux H; Heise N; Klenner T; Hart D; Opperdoes FR
Mol Biochem Parasitol; 2000 Nov; 111(1):1-14. PubMed ID: 11087912
[TBL] [Abstract][Full Text] [Related]
17. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG
J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860
[TBL] [Abstract][Full Text] [Related]
18. Anti-
Cruz MGFdML; Santi AMM; Morais-Teixeira Ed; Caldeira ASP; Siqueira EPd; Oliveira E; Alves TMdA; Murta SMF
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0050923. PubMed ID: 38063403
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
